Nautilus Biotech, raised Euros 8.4 million from Creabilis Biotech, Ed de Rothschild Investment Partners, Auriga Partners, Matignon Technologies, Pre-IPO Invest, FCJE, 123 Ventures and Genopole.
The money will fund the initial clinical development of the Paris-based company’s two lead products, Belerofon and Vitatropin, proprietary variants of human interferon alpha and human growth hormone, respectively. Each has a single amino acid replacement, making them both long-lasting in serum following injection and, for the first time, orally available.
Earlier this month Nautilus initiated a US Phase I clinical trial of subcutaneous Belerofon, while in February it submitted an US Investigational New Drug filing for oral Belerofon. The company expects to submit an IND filing for Vitatropin in 2007 also.
Philippe Peltier, Partner at Auriga Partners said Nautilus has made significant progress to date. “The continuing support of existing investors demonstrates the confidence we have in the company, its strategic goal of developing protein drugs with significantly improved therapeutic profiles, and its ability to form partnerships with the pharmaceutical industry,”
The money will fund the initial clinical development of the Paris-based company’s two lead products, Belerofon and Vitatropin, proprietary variants of human interferon alpha and human growth hormone, respectively. Each has a single amino acid replacement, making them both long-lasting in serum following injection and, for the first time, orally available.
Earlier this month Nautilus initiated a US Phase I clinical trial of subcutaneous Belerofon, while in February it submitted an US Investigational New Drug filing for oral Belerofon. The company expects to submit an IND filing for Vitatropin in 2007 also.
Philippe Peltier, Partner at Auriga Partners said Nautilus has made significant progress to date. “The continuing support of existing investors demonstrates the confidence we have in the company, its strategic goal of developing protein drugs with significantly improved therapeutic profiles, and its ability to form partnerships with the pharmaceutical industry,”
Receive our news bulletin each Tuesday & Thursday and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
